Antibiotic Efficacy in Pneumonitis Following Paraffin (Kerosene) Ingestion in Children

NCT ID: NCT01253980

Last Updated: 2015-11-09

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

74 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-07-31

Study Completion Date

2011-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Paraffin (kerosene) ingestion in the developing world accounts for a large number of visits to healthcare facilities, especially amongst children. There is no evidence in animals and no good evidence in humans that the use of early antibiotics improves the clinical outcome of paraffin-induced pneumonitis. This randomised placebo-controlled trial will investigate whether the use of early antibiotics affects the clinical course of children with pneumonitis following paraffin ingestion.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The average of 100 children per annum attending Red Cross War Memorial Children's Hospital 9RCWMCH) with the diagnosis of kerosene ingestion would give a sample of 200 children over a two-year period, with 100 patients in each group. From a postulated secondary infection rate of 15 to 50% for children not receiving an antibiotic, a midway point of 25% estimated the treatment failure rate in the placebo group. With no information available on the treatment failure rate in the active group, failure rates of 10% and 5% were arbitrarily applied. With 25% and 5% treatment failure rates for placebo and active groups respectively, at a level of significance of α = 0.05 a sample size of 100 per group gives a power of 0.98 and with failure rates of 25% and 10% a power of 0.80.

Statistical analysis was done using IBM SPSS Version 20 (SPSS Inc., Chicago, IL, USA). Categorical variables are expressed as n (%) and continuous variables as median (interquartile range (IQR)). A P value of ≤ 0.05 was considered significant for all situations. For categorical variables, Fischer's exact test was used for small samples or less frequent occurrences. Chi-Square testing was applied for larger samples or more frequent occurrences. Mann-Whitney or Kruskal-Wallis tests were used for ordinal and continuous variables. Significant correlation between factors and covariates (Spearman's rank coefficient) favoured univariate analysis over binary logistic regression modelling to determine potential risk factors for treatment failure. Continuous variables were categorised for clinical relevance or logistic regression testing. In some instances, specific clinical parameters or reported symptoms were not recorded or the presence or absence of a risk factor was unknown. The missing values, unknown factors and the flow of patient follow-up account for totals not always adding up to the full number of study participants. In the results for Day 3 and Day 5 post-ingestion, the denominator used to calculate proportions for reported symptoms included those patients who attended and who were telephone interviewed, whereas the denominator for clinical signs was only the patients who attended.

The primary outcome measure was treatment failure, as reported. Secondary outcome measures were length of hospital stay, reported symptoms (cough, shortness of breath, wheeze and fever) and clinical signs (respiratory rate, flaring, recessions, grunting, wheeze, crepitations, temperature and altered mental status) at follow-up at Day 3 and 5 post-ingestion for placebo and active groups. Further investigation explored the role of confounding conditions (upper respiratory tract infection, active Mycobacterium tuberculosis infection) and risk factors for treatment failure or delayed resolution (vomiting post-ingestion, household smoking contact, HIV exposure status, prior respiratory history, young age etc). Secondary outcome measures, confounding conditions and risk factors are not reported in this Clinical Trials format, but are reported in the PI's Master's thesis. (Balme KH. The efficacy of prophylactic antibiotics in the management of pneumonitis following paraffin (kerosene) ingestion in children \[Master's thesis\]. \[Cape Town\]: University of Cape Town; 2013. 113 p.)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Kerosene Pneumonitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Amoxicillin

Amoxicillin

Group Type ACTIVE_COMPARATOR

Amoxicillin

Intervention Type DRUG

Amoxicillin syrup 20-30mg/kg 8 hourly for 5 days

Placebo suspension

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo suspension made of water, dextrose and glycerine with a similar taste and appearance to the active comparator.

Dose 20-30mg/kg 8 hourly for 5 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Amoxicillin

Amoxicillin syrup 20-30mg/kg 8 hourly for 5 days

Intervention Type DRUG

Placebo

Placebo suspension made of water, dextrose and glycerine with a similar taste and appearance to the active comparator.

Dose 20-30mg/kg 8 hourly for 5 days

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Ingestion in the preceding 24 hours
* Presence of respiratory symptoms and/or signs at presentation
* Informed consent obtained from parent or legal guardian
* Resident within the Red Cross Hospital drainage area and able to come for two follow-up appointments

Exclusion Criteria

* Asymptomatic and no clinical signs
* Too ill to be excluded from receiving an antibiotic as judged by:

* Requiring more than 2L/min nasal-prong oxygen
* Requiring continuous or intermittent positive airway pressure ventilation
* Fever \> 40˚C
* Needing an antibiotic for another reason e.g. otitis media, tonsillitis
* Current antibiotic use, prior to kerosene ingestion
* Allergic to amoxicillin
Minimum Eligible Age

3 Months

Maximum Eligible Age

13 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Cape Town

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Kate Balme

Dr

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Heather Zar, MBBCh PhD

Role: STUDY_DIRECTOR

University of Cape Town

Michael D Mann, MMed Paed PhD

Role: STUDY_DIRECTOR

University of Cape Town

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Red Cross War Memorial Children's Hospital

Cape Town, Western Cape, South Africa

Site Status

Countries

Review the countries where the study has at least one active or historical site.

South Africa

References

Explore related publications, articles, or registry entries linked to this study.

Balme KH, Zar H, Swift DK, Mann MD. The efficacy of prophylactic antibiotics in the management of children with kerosene-associated pneumonitis: a double-blind randomised controlled trial. Clin Toxicol (Phila). 2015;53(8):789-96. doi: 10.3109/15563650.2015.1059943. Epub 2015 Jun 26.

Reference Type RESULT
PMID: 26114347 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PACTR201201000259370

Identifier Type: REGISTRY

Identifier Source: secondary_id

095/2010

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Therapeutic Zinc in Childhood Pneumonia
NCT00252304 COMPLETED PHASE2/PHASE3
Zinc and Pneumonia Protocol
NCT00133432 TERMINATED PHASE3
WASH Benefits Kenya
NCT01704105 COMPLETED NA